Drugs / DNase
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01717742 | Dec 2012 → Dec 2017 | pleural empyema | The Hospital for Sick Children | Completed | Missed primary |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT03873766 | Apr 2019 → Mar 2022 | empyema, pleural empyema | Swedish Medical Center | Completed | Met primary |
| Phase 4 | NCT03167281 | Feb 2017 → Mar 2021 | — | Prisma Health-Midlands | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT02193490 Comparator | Jul 2014 → Oct 2017 | dry eye syndrome | University of Illinois at Chicago | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT03213834 Comparator | Sep 2017 → Feb 2020 | pleural disorder | University of Florida | Completed | No outcome recorded |
| — | NCT05903417 Comparator | Jul 2023 → Oct 2025 | respiratory tract infectious disorder | National University of Malaysia | Completed | No outcome recorded |
Press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNase | “Patients randomized to the IPFT study arm will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg BID x 3 days delivered through a chest tube or small bore catheter...” NCT03873766 ↗5“t-PA (Alteplase) 5mg and DNase (Pulmozyme)5mg” NCT05903417 ↗ |
| Known as | Pulmozyme | “t-PA (Alteplase) 5mg and DNase (Pulmozyme)5mg” NCT05903417 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Deoxyribonuclease” NCT02193490 ↗ |
| Route | Other | “3 daily administrations of intrapleural tPA, 4 mg, followed by DNase, 5 mg” PMID 32011642 ↗ Apr 2020 |